BioLLM Wiki โ€บ Disease Indications

Lung Cancer

These papers examine non-small cell and small cell lung cancer, focusing on resistance to osimertinib or PARP inhibitors, immune responses to neoadjuvant immunotherapy, molecular biomarkers, spread through air spaces, and treatment planning or prediction of treatment outcomes. Approaches include cell-based studies, in vivo tumor models, clinical cohorts, liquid biopsy, 18F-FDG PET/CT, proteomic, T-cell receptor, cytokine, and immunohistochemical analyses, deep learning, and targeted drug-delivery nanocages.

Papers
3,902
Jan 2024 โ€“ Aug 2026
2024 share
3.40%
of the month's papers, on average
2025 share
3.33%
of the month's papers, on average
2026 share
3.17%
of the month's papers, on average
Change
โ–ผ -6.8%
2024 โ†’ 2026, relative

Share of papers by month

Peak 4.29% in Jan 2024. Month-by-month values and sub-terms are on Keyword Trends.

Jan 2024Aug 2026

EGFR Resistance Mechanisms

Several studies investigate mechanisms of persistence, resistance, and treatment outcomes during osimertinib treatment in EGFR-mutant lung adenocarcinoma or NSCLC. SOS2 deletion reduced PI3K/AKT reactivation and sensitized EGFR-mutant cells to osimertinib, whereas DUSP1 was overexpressed in osimertinib-resistant NSCLC cells, and DUSP1 silencing attenuated resistance and restored osimertinib sensitivity by activating MAPK signaling (PMIDs 38073064, 38551790). A prospective study evaluated serial circulating tumor DNA and 18F-FDG PET/CT metabolic parameters as noninvasive predictors of osimertinib outcome, while a retrospective single-center cohort examined HER3 expression as a potential prognostic and primary TKI resistance-related factor in EGFR-mutant NSCLC (PMIDs 39198088, 41901620).

๐Ÿ“„ Molecular oncology โ†—๐Ÿ“„ Molecular biotechnology โ†—๐Ÿ“„ Clinical lung cancer โ†—๐Ÿ“„ Medicina (Kaunas, Lithuania) โ†—

Immunotherapy Response And Escape

The papers assess biomarkers and mechanisms associated with outcomes of immune checkpoint treatment in NSCLC. Lower baseline soluble PD-L1 levels were associated with longer progression-free survival in patients receiving envafolimab plus Endostar, while higher posttreatment VEGF levels were associated with progressive disease and shorter progression-free survival (PMID 38386011). Low baseline SDF-1ฮฑ was associated with unfavorable disease-free survival after neoadjuvant immunotherapy (PMID 39190094). In a mouse model of NSCLC, the TIGIT-CD226-PVR axis was associated with functional decline and exhaustion of CD27+/CD127+ T cells; inhibiting TIGIT-PVR while activating CD226-PVR restored T-cell proliferation and effector function, and targeting the axis enhanced cytotoxicity against NSCLC cells and improved immunotherapy efficacy (PMID 39725799). Antibiotic use was associated with progression-free and overall survival among patients with advanced metastatic NSCLC receiving immune checkpoint inhibitors, with use within 30 days before or after immunotherapy associated with shorter survival (PMID 39302841).

๐Ÿ“„ Anti-cancer drugs โ†—๐Ÿ“„ Annals of surgical oncology โ†—๐Ÿ“„ Apoptosis : an international journal on programmed cell death โ†—๐Ÿ“„ European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) โ†—

Computational Biomarkers And Imaging

Machine-learning studies use molecular, immune, and imaging features to stratify prognosis or treatment response in lung adenocarcinoma. A neutrophil-extracellular-trap gene signature, a CKS1B+ tumor-cell signature derived from single-cell data, and a cancer-driver-gene model were developed to predict survival, immune features, chemotherapy sensitivity, or immunotherapy response (PMIDs 38519636, 38946232, 39292390). Imaging models used fused PET/CT deep learning to predict spread through air spaces and dynamic CT radiomics to estimate progression-free survival during EGFR-TKI therapy (PMIDs 39994163, 40114622).

๐Ÿ“„ Apoptosis : an international journal on programmed cell death โ†—๐Ÿ“„ Cell proliferation โ†—๐Ÿ“„ Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico โ†—๐Ÿ“„ Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico โ†—๐Ÿ“„ Thoracic cancer โ†—

Targeted And Engineered Therapies

Therapeutic studies examined PARP inhibition, lineage-specific oncoprotein degradation, WEE1 inhibition, and tumor-delivery strategies. In SCLC, PARP inhibition induced HUWE1-dependent proteasomal degradation of ASCL1, and combining PARP inhibitors with [177Lu]Lu-DOTA-TOC increased the potency of SSTR2-targeted therapy in SSTR2-low-expressing SCLC models; in KRAS-mutant TP53-mutant NSCLC, WEE1 inhibition reduced CHK2 and Rad51 expression and promoted mitotic catastrophe (PMIDs 38241363, 39023784, 38776912). Delivery approaches included human heavy-chain ferritin nanocages carrying the ALK-targeting PROTAC MS4078, inhalable redox-responsive protein nanoparticles carrying curcumin, and a fully human anti-Ts7TMR scFv that inhibited A549 lung cancer growth in nude mice while reducing PCNA and VEGF expression (PMIDs 40712494, 39689461, 38753524).

๐Ÿ“„ Science advances โ†—๐Ÿ“„ European journal of nuclear medicine and molecular imaging โ†—๐Ÿ“„ Cell reports. Medicine โ†—๐Ÿ“„ Colloids and surfaces. B, Biointerfaces โ†—๐Ÿ“„ Biomaterials โ†—๐Ÿ“„ Artificial cells, nanomedicine, and biotechnology โ†—

Local Treatment And Surgical Selection

Clinical studies examine how imaging, patient characteristics, and tumor morphology guide local treatment for early-stage NSCLC. A prediction model was developed to distinguish patients treated with stereotactic body radiotherapy or minimally invasive surgery, while a retrospective cohort evaluated empiric SBRT for presumed early-stage disease without histopathologic confirmation (PMIDs 39351678, 40760181). Surgical studies assessed whether lymph-node dissection could be omitted for small peripheral ground-glass-opacity-dominant tumors and compared perioperative outcomes of multi-arm uniportal robotic-assisted versus uniportal video-assisted thoracoscopic segmentectomy for stage IA NSCLC (PMIDs 38513985, 42474805).

๐Ÿ“„ Annals of surgery โ†—๐Ÿ“„ Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] โ†—๐Ÿ“„ The Annals of thoracic surgery โ†—๐Ÿ“„ Journal of robotic surgery โ†—

Written by gpt-5.6-luna from 96 of this keyword's papers, a few from every whole month through Aug 2026; every paragraph was checked against the abstracts it cites. A paper counts for the keyword when its title, abstract, keywords or MeSH headings match the keyword's terms. Not medical advice; see the Disclaimer.